I. Vitamin K Deficiency
1. Introduction and report on the vitamin K international symposium by Dr. T. Sutor (Germany).Unfortunately, several presenters did not arrive. However, the extra time was effectively used for a full subcommittee discussion on recommendations to be included in an official publication from ISTH. Issues discussed were: terminology, definition, diagnosis, classification, prophylaxis.

II. Coagulation Protein Concentrates

Homozygous Protein C Deficiency

1. Ms. L. Mitchell (Canada) presented data on the subcutaneous administration of protein C in rabbits. Survival of protein C in an active form was observed for 77 hours.
2. Dr. M. David (Canada) reported on the successful subcutaneous administration of protein C concentrate in a young child for 48 hours.
3. Dr. P. Shwartz (Austria) updated the subcommittee on the intravenous use of protein C concentrate worldwide.
4. A presentation of the questions regarding dosage, response, pharmacokinetics, and risks of the use of coagulation protein concentrates in newborns was given by Dr. M. Dreyfus (France). There was general support from the subcommittee for the establishment of a registry.

III. International Trials in Perinatal Haemostasis

1. A brief summary of childhood thrombophilia was given by M. Andrew (Canada). There was agreement that the name of the subcommittee should be changed to Perinatal/Pediatric Subcommittee. Enormous interest was expressed by the audience. There was agreement that international studies in the prevention and treatment of thrombotic disease were needed and could be facilitated by the subcommittee.

2. A summary on the use of estrogen in women was given by Dr. J. Deuketis (Canada). The discussion focused on the need for clinical trials but that they may not be feasible (legally) in some countries.

IV. Mini Reports

1. Dr. Suzuki (Japan) reported on the use of the thrombostat 4000 in evaluating prethrombostat effects of pregnancy and oestrogen use.

2. Dr. C. Kaplan (France) reported on the treatment of the fetus with allo-immune thrombocytopenia. The need for individual clinicians to collaborate on studies addressing optimal treatment was accepted by the subcommittee.